SCHEMBL683665

SCHEMBL683665

Cc1ccc(N2CCN(Cn3c(=O)c4c(ncn4C)n(C)c3=O)CC2)cc1C

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2B P29275 7/20 0.47
HTR2A P28223 1/20 0.47
GLA P06280 1/20 0.46
BLM P54132 1/20 0.46
MAPK1 P28482 2/20 0.45
TNF P01375 2/20 0.44
NPSR1 Q6W5P4 1/20 0.44
USP2 O75604 1/20 0.43
LMNA P02545 1/20 0.43
CYP1A2 P05177 1/20 0.43
TSHR P16473 1/20 0.43
NFKB1 P19838 1/20 0.43
ACHE P22303 1/20 0.43
PDE4A P27815 1/20 0.43
PMP22 Q01453 1/20 0.43
PDE4B Q07343 1/20 0.43
PDE4C Q08493 1/20 0.43
PDE4D Q08499 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
RXFP1 Q9HBX9 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL682830 0.88 ADORA2B (0.50) ADORA2BHTR2AGLABLMTNF
SCHEMBL684026 0.87 MAPK1 (0.49) ADORA2BHTR2AGLABLMMAPK1
SCHEMBL683653 0.87 ADRA1D (0.52) ADORA2BHTR2AGLABLMMAPK1
SCHEMBL684023 0.85 HTR2A (0.58) ADORA2BHTR2AGLABLMMAPK1
SCHEMBL683652 0.84 MAPK1 (0.55) HTR2AGLAMAPK1TNFNPSR1
SCHEMBL682828 0.84 ADORA2B (0.46) ADORA2BHTR2AGLABLMMAPK1
SCHEMBL684375 0.83 ADORA2B (0.53) ADORA2BHTR2AMAPK1NPSR1LMNA
SCHEMBL683640 0.83 HTR2A (0.51) ADORA2BHTR2AGLABLMMAPK1
SCHEMBL684068 0.83 ADORA2B (0.50) ADORA2BHTR2AMAPK1RXFP1
SCHEMBL683668 0.82 ADORA2B (0.49) ADORA2BHTR2AGLABLMTNF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110269717-A1 NEUROGENESIS BY MODULATING ANGIOTENSIN BRAINCELLS INC. (US) 2011-11-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110269717-A1 NEUROGENESIS BY MODULATING ANGIOTENSIN NGF, DCX, BDNF ADORA2B 786/4885HTR2A 1201/4885GLA 1358/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.